BCR-ABL multipeptide vaccine

BCR-ABL multipeptide vaccine is an investigational **peptide-based therapeutic cancer vaccine** evaluated in chronic myeloid leukemia. In the registered Tehran University of Medical Sciences study NCT00455221, the vaccine consisted of ten BCR-ABL-derived peptides administered subcutaneously to patients receiving imatinib. The intended mechanism is induction of BCR-ABL-specific cellular immunity, including cytotoxic T-cell responses against leukemic cells expressing the BCR-ABL fusion oncoprotein. The trial evaluated the vaccine together with separately administered IL-12 and GM-CSF plasmid cytokine-gene adjuvants; those plasmids are not considered part of the BCR-ABL multipeptide vaccine itself.

Other names

bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccinebcr-abl (b3a2)-derived peptide vaccinep210 multipeptide vaccinep-210 multipeptide vaccinep 210 multipeptide vaccine